Cancer as a Metabolic Disease

The heart of Seyfried's argument is that the metabolic disturbance Warburg saw is not incidental — it is close to universal across cancers, and it points back to the mitochondria. Whatever tissue a tumor arises in, whatever mutations it carries, the cells tend to lean on fermentation for energy. Seyfried reads this as evidence that damaged or dysfunctional mitochondria sit near the origin of the disease, and that the genetic chaos so prominent in tumors is downstream of that damage rather than the source of it.

The mechanism he proposes runs in the opposite direction from the standard story. In the genetic model, mutations come first: they corrupt the cell's controls, and metabolism goes haywire as a consequence. Seyfried, building on Warburg and on the work of researchers who studied energy metabolism, argues that impaired respiration comes first. When a cell can no longer generate energy efficiently through its mitochondria, it is pushed toward fermentation, and the stress of that broken energy supply destabilizes the genome, producing the mutations that everyone counts. The genes are the smoke, not the fire.

To understand why Warburg was shelved, it helps to see what replaced him. After mid-century, cancer research organized itself around the somatic mutation theory: cancer is caused by accumulated damage to the DNA, mutations that switch on growth-promoting genes and switch off the brakes. This became the reigning paradigm, and it produced the ambitious effort to catalog every mutation in every tumor type. The promise was that if we mapped the corrupted instructions precisely enough, we could design drugs to target them.

Seyfried does not deny that tumors are full of mutations. His challenge is to the assumption that those mutations are the cause. He points to the awkward findings that the gene theory struggles to absorb. Tumors of the same type often share almost no mutations in common, and some cancer cells carry no clear driver mutation at all. Meanwhile the metabolic shift toward fermentation shows up almost everywhere, cutting across the genetic diversity. If the mutations were the root, he asks, why is the metabolism more consistent than the genetics?

What is really at stake in Warburg versus the gene theory is not a single fact but the choice of an origin story — and origin stories quietly dictate everything that follows. Decide that cancer is a genetic disease, and the research program becomes sequencing tumors, cataloging mutations, and designing drugs aimed at specific corrupted proteins. Decide that it is a metabolic disease, and the program shifts toward the cell's fuel supply: what a tumor eats, how it makes energy, and what happens when that supply is cut. The same disease, seen through two maps, yields two entirely different sets of questions.

Seyfried's map leads somewhere concrete. If cancer cells depend on fermenting glucose and glutamine, then starving them of those fuels should press on a weakness that healthy cells, with their intact respiration, can tolerate. This is the logic behind his interest in metabolic strategies — dietary approaches that lower blood glucose and raise ketone bodies, which normal cells can burn for energy but fermenting tumor cells largely cannot. The aim is to exploit a difference in metabolism the way older therapies exploit differences in how fast cells divide.

Otto Warburg died in 1970, still convinced that cancer began in the failure of a cell to breathe, still largely ignored on that point by a field racing toward DNA. The instruments he built to measure oxygen and lactic acid have long been superseded, but the readings he took have never really been explained away. The fermenting tumor cell he described in the 1920s is the same one that turns up in a modern laboratory, consuming sugar as if it were suffocating in open air.